Zenas BioPharma, Inc. (ZBIO)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
Zenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with pro forma balances covering operations into late 2028, though financing risk remains if FDA approval is delayed. Obexelimab's non-depleting B cell inhibition offers a differentiated safety profile versus Uplizna, targeting chronic use in older patients and potentially expanding the addressable market.
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026
Zenas BioPharma, Inc. maintains a Strong Buy rating, driven by obexelimab's positive phase 3 results in IgG4-RD and regulatory filings planned for 2026. ZBIO is advancing obexelimab into the large SLE market, with phase 2 SunStone topline and biomarker data expected in Q4 2026. Pipeline expansion includes ZB014, a half-life extended anti-CD19/FcγRIIb mAb aiming for once-monthly dosing, and CNS-penetrant BTK inhibitor orelabrutinib in phase 3 for MS.
Zenas BioPharma, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 20 | $391.43 | $497.2 | $105.77 | 27.02% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 370 | $7,233.5 | $9,198.2 | $1,964.7 | 27.16% |
| KM Kristin Mariani Janus Henderson Group PLC | 7,900 | $286,573 | $196,236 | -$90,337 | -31.52% |
| CD Charlie Durham Sterling Capital Management LLC | 100 | $2,219.98 | $2,486 | $266.02 | 11.98% |
 Point72 Asset Management LP Point72 Asset Management LP | 16,136 | $301,904.56 | $409,854.4 | $107,949.84 | 35.76% |
Zenas BioPharma, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Yigal Nochomovitz Citigroup | 787.55 | $21,240.14 | $19,523.29 | -$1,716.85 | -8.08% |
Zenas BioPharma, Inc. (ZBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zenas BioPharma, Inc. ever had a stock split?
Zenas BioPharma, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Leon Oliver Moulder Jr. CEO | NASDAQ (NGS) Exchange | 98937L105 CUSIP |
| US Country | 167 Employees | - Last Dividend | 24 May 2018 Last Split | - IPO Date |
Overview
The investment fund is designed to offer investors a unique opportunity to capitalize on the performance of the biotechnology and pharmaceutical sectors, with a specific focus on the NASDAQ Biotechnology Index®. It aims to achieve daily investment results, prior to fees and expenses, that are three times the inverse (-3x) of the daily performance of the aforementioned index. This indicates that the fund seeks to profit from declines in the index's value. Managed by ProShare Advisors, the strategy involves investing in a variety of financial instruments that, in combination, are expected to generate daily returns aligned with the fund's investment goal. The fund's approach mirrors the volatility and movement of the biotechnology and pharmaceutical sectors, making it a non-diversified fund. This means it may invest a larger portion of its assets in fewer securities, potentially increasing the risk and volatility compared to diversified funds.
Products and Services
- Inverse Performance to NASDAQ Biotechnology Index®
The primary service offered by the fund is its investment strategy that attempts to deliver thrice the inverse (-3x) of the daily movement of the NASDAQ Biotechnology Index®. This index includes companies listed on the Nasdaq stock market that are classified within the biotechnology or pharmaceutical sectors, adhering to a modified capitalization-weighted methodology. This service is especially appealing to investors looking for a hedge against declines in the biotechnology and pharmaceutical industries or those speculating on the negative movements within these sectors. It's a sophisticated financial tool that requires understanding of the risks involved, including the potential for significant losses, especially in volatile market conditions.
Contact Information
